Solid Biosciences Announces Closing Of Acquisition Of Aavantibio And Concurrent $75 Million Private Placement
Acquiring Company
Solid Biosciences
Acquired Company
AavantiBio, Inc.
CharlestownGainesvilleBiotechnologyHealthcareHealth CareGeneticsTherapeuticsBiotechnologyHealth CareGeneticsTherapeuticsDescription
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the closing of its acquisition of AavantiBio, a privately held gene therapy company focused on transforming the lives of patients with Friedreich’s ataxia and rare cardiomyopathies, including its pipeline assets and net cash. The combined company will focus on advancing a portfolio of neuromuscular and cardiac programs, including SGT-003, a differentiated gene transfer candidate, for the treatment of Duchenne, AVB-202, a gene transfer candidate for the treatment of Friedreich’s ataxia, AVB-401 for BAG3 mediated dilated cardiomyopathy, and additional assets for the treatment of undisclosed cardiac diseases. Bo Cumbo, the Chief Executive Officer of AavantiBio, will assume the role of President and CEO of Solid Biosciences.
Quick answer
Solid Biosciences is acquiring AavantiBio, Inc. for $75 million, announced December 5, 2022. Solid Biosciences is based in Charlestown, Massachusetts, United States.
- Who acquired AavantiBio, Inc?
- Solid Biosciences agreed to acquire AavantiBio, Inc. on December 5, 2022.
- How much did Solid Biosciences pay for AavantiBio, Inc?
- The reported deal value is $75 million.
- What does Solid Biosciences do?
- Solid Biosciences is a life sciences company focused on advancing a portfolio of gene therapy candidates and neuromuscular and cardiac programs, including SGT-003, for the treatment of Duchenne muscular dystrophy..
- Where are Solid Biosciences and AavantiBio, Inc. based?
- Solid Biosciences is based in Charlestown, Massachusetts, United States. AavantiBio, Inc. is based in Gainesville, Florida, United States.
Source: Fundz verified event record.
Other recent acquisitions in Healthcare and Genetics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Solid Biosciences Announces Stockholder Approval Of Acquisition Of Aavantibio (December 1, 2022)
- Rocket Pharmaceuticals Completes Acquisition Of Renovacor (December 1, 2022)
- Merck Completes Tender Offer To Acquire Imago Biosciences, Inc. (January 11, 2023)
- Merck To Acquire Imago Biosciences, Inc. (November 21, 2022)
- Shockwave Medical Announces Agreement To Acquire Neovasc (January 17, 2023)
- Shockwave Medical To Acquire Neovasc (January 17, 2023)
Who to call at Solid Biosciences, and when
When Solid Biosciences changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Solid Biosciences raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Solid Biosciences, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Solid Biosciences. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Solid Biosciences makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired AavantiBio, Inc.?
AavantiBio, Inc. was acquired by Solid Biosciences, based in Charlestown. The deal was reported on December 5, 2022. Solid Biosciences is publicly traded (SLDB) and operates in Biotechnology.
When did Solid Biosciences acquire AavantiBio, Inc.?
Solid Biosciences's acquisition of AavantiBio, Inc. was reported on December 5, 2022. Solid Biosciences Inc. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does AavantiBio, Inc. do?
It is privately held, operating in Biotechnology, and is based in Gainesville.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.